Legacy Capital Group California Inc. Acquires Shares of 10,109 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Legacy Capital Group California Inc. bought a new position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the fourth quarter, HoldingsChannel reports. The firm bought 10,109 shares of the company’s stock, valued at approximately $223,000.

Several other large investors have also recently modified their holdings of TEVA. Smithfield Trust Co lifted its position in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $50,000. Ameliora Wealth Management Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $66,000. Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $60,000. Finally, Farther Finance Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 273.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,538 shares of the company’s stock valued at $82,000 after purchasing an additional 3,323 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Piper Sandler boosted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, Barclays decreased their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $16.75 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business has a 50-day moving average price of $19.92 and a 200 day moving average price of $18.48. Teva Pharmaceutical Industries Limited has a 1-year low of $12.51 and a 1-year high of $22.80. The company has a market capitalization of $18.97 billion, a P/E ratio of -11.55, a PEG ratio of 1.39 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.61 EPS for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.